Ensemble Therapeutics, a biotechnology company developing Ensemblins, a novel class of small molecule therapeutics with the power of biologics, announced the initiation of a drug discovery collaboration with Genentech, a member of the Roche Group, to discover macrocyclic drug candidates against targets specified by Genentech.
The collaboration will deploy Ensemble’s proprietary drug discovery platform, including its Ensemblin collection of over 5 million macrocycles, to discover novel drug candidates against Genentech’s drug targets. Genentech will have the right to develop and commercialize lead molecules arising from the collaboration.
Under the terms of the agreement, Ensemble will receive an undisclosed upfront payment and milestone payments upon the successful achievement of certain development milestones. In addition, Ensemble is eligible to receive royalties on future sales of products that arise from the collaboration.
“This collaboration further validates the wide-ranging potential of our Ensemblin drug discovery platforms while providing Ensemble with additional resources to advance our own internal pipeline,” said Dr. Michael D. Taylor, CEO of Ensemble Therapeutics.
James Sabry, Genentech’s Vice President of Partnering, said, “We believe Ensemble’s approach to develop macrocyclic small molecules to address drug discovery targets that have proven difficult to modulate with traditional approaches could result in innovative new medicines.”
The collaboration with Genentech builds on Ensemble’s business model to partner with drug development leaders, with this as the third collaboration with a major pharmaceutical company, to leverage the Ensemblin discovery engine to identify novel macrocyclic drug candidates.
Date: May 29, 2012
Source: Ensemble Therapeutics
Filed Under: Drug Discovery
